86 FR 217 pgs. 63061-63067 - Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021

Type: NOTICEVolume: 86Number: 217Pages: 63061 - 63067
Docket number: [Docket No. DEA-688F]
FR document: [FR Doc. 2021-24921 Filed 11-10-21; 4:15 pm]
Agency: Justice Department
Sub Agency: Drug Enforcement Administration
Official PDF Version:  PDF Version
Pages: 63061, 63062, 63063, 63064

[top] page 63061

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-688F]

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021

AGENCY:

Drug Enforcement Administration, Department of Justice.

ACTION:

Final order.

SUMMARY:

This final order establishes the final adjusted 2021 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES:

This order is effective November 15, 2021.

FOR FURTHER INFORMATION CONTACT:

Scott A. Brinks, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (571) 362-3261.

SUPPLEMENTARY INFORMATION:

Legal Authority

Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas (APQ) for each basic class of controlled substances listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the Drug Enforcement Administration (DEA) pursuant to 28 CFR 0.100.

Background

DEA published the 2021 established APQ for controlled substances in schedules I and II and for the assessment of annual needs (AAN) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the Federal Register on November 30, 2020. 85 FR 76604. DEA is committed to preventing and limiting diversion by enforcing laws and regulations regarding controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, while meeting the legitimate medical, scientific, and export needs of the United States. This notice stated that the Administrator would adjust, as needed, the established APQ in 2021 in accordance with 21 CFR 1303.13 and 21 CFR 1315.13.

The 2021 proposed adjusted APQ for controlled substances in schedules I and II and AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine were subsequently published in the Federal Register on September 2, 2021, (86 FR 49346), after consideration of the criteria outlined in that notice. All interested persons were invited to comment on or object to the proposed APQs and AANs on or before October 4, 2021.

Comments Received

DEA received 27 timely comments in response to the September Federal Register notice from patients, DEA-registered entities, and non-DEA entities. The comments included appreciation of DEA's response to the increased interest in research using hallucinogenic controlled substances, requests to increase the APQ for additional hallucinogenic controlled substances, requests to increase the APQ for select schedule II controlled substances, concerns regarding the inability to comment to the notice electronically for two weeks, and comments outside the scope of this final order.

Issue: Commenters expressed appreciation of DEA's flexibility in responding to the nationwide public interest in hallucinogenic controlled substances research.

DEA Response: DEA acknowledges the expressions of appreciation to changes in the APQ for these controlled substances. The adjustments to select hallucinogenic schedule I controlled substances occurred after DEA received additional schedule I researcher protocols from DEA registered researchers and quota applications from DEA registered manufacturers.


[top] Issue: Commenters requested DEA to increase the APQ for Bufotenine, Dimethyltryptamine (DMT), N,N-Dimethyltryptamine, 5-Methoxy-N,N- page 63062 dimethyltryptamine (5MEODMT), Ibogaine, Ketamine, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA), Mescaline, Mitragynine, and Psilocybin in response to the nationwide public interest in hallucinogenic controlled substances research.

DEA Response: Ketamine is a schedule III controlled substance and therefore is outside of the scope of this final order as DEA only sets APQs for substances controlled in schedules I and II. DEA received additional quota applications for DMT, MDMA, and Psilocybin and considered the timely provided information in those applications for this final order. Regarding the other controlled substances listed, DEA has not received quota applications from DEA-registered manufacturers to support the requested changes in the APQ for these controlled substances. Mitragynine is not a controlled substance and therefore is outside the scope of this final order.

Issue: DEA-registered entities requested that the APQ for Methadone, Methadone Intermediate, Methylphenidate Oxycodone (for sale), Phenylacetone, and Thebaine be sufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements, and for the establishment and maintenance of reserve stocks.

DEA Response: DEA sets APQ in a manner to ensure that the estimated medical, scientific, research, industrial needs of the United States, lawful export requirements, and for the establishment and maintenance of reserve stocks. As discussed in the notice for adjustment, any adjustments to the APQ for a controlled substance are based on factors set forth in 21 CFR 1303.13. In the event of a shortage, the CSA provides a mechanism under which DEA will, in appropriate circumstances, increase quotas to address shortages. 21 U.S.C. 826(h). Under 21 U.S.C. 826(h)(1), after receiving a request to address a shortage, DEA has 30 days to complete review of the request and determine whether adjustments are necessary to address the shortage. If adjustments are necessary, DEA is required to increase the APQ and individual production quotas to alleviate the shortage. Id. If DEA determines adjustments are not necessary, DEA is required to "provide a written response detailing the basis for the . . . determination." Id. In addition to what Section 826(h)(1) requires, when DEA is notified of an alleged shortage, DEA will confer with the Food and Drug Administration and relevant manufacturers regarding the amount of material in physical inventory, current quota granted, and the estimated legitimate medical need, to determine whether a quota adjustment is necessary to alleviate any quota-related drug shortage.

In accordance with 21 CFR 1303.13, DEA considered the comments for Bufotenine, 5-Methoxy-N,N-dimethyltryptamine (5MEODMT), Ibogaine, Lysergic Acid Diethylamide (LSD), Mescaline, Methadone, Methadone Intermediate, Oxycodone (for sale), and Thebaine and the Administrator determined the proposed adjusted 2021 APQs for these substances as published in the Federal Register on September 2, 2021, (86 FR 49346), are sufficient to meet the current 2021 estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and to provide for adequate reserve stock.

Issue: Commenters expressed general concerns regarding the inability to submit electronic comments to the notice published on September 2, 2021, for two weeks. Commenters requested an extension of the comment period to allow for additional comments.

DEA Response: DEA acknowledges that commenters could not submit electronic comments to the notice for two weeks. However, written comments could be submitted via mail to the address provided in the notice. Written comments that were postmarked on or before October 4, 2021, were considered in this final order. DEA notes that one commenter submitted identical electronic and written comments both of which were timely postmarked, received, and considered for this final order.

Out of Scope Comments: DEA received comments on issues outside the scope of this final order. Commenters made several suggestions to the DEA, including: (1) Seeking assistance from indigenous communities to determine the amount of psychedelic substances that would be needed to conduct research; (2) making the United States a signatory to the Nagoya Protocol and the Convention on Biological Diversity; and (3) creating diversified categories for production and research on psilocybin-containing fungi fruiting bodies/sclerotia/liquid culture similar to cannabis (flower), fruiting body extract (akin to cannabis extract), and psilocybin and psilocin separately as purified compounds (akin to delta-9-thc). Regarding this last suggestion, the commenter further suggested that the "same system should then be replicated in regards to lophophora/mescaline, as well as other plants, fungi and lifeforms, which produce these compounds being used in whole or closer to whole ways."

DEA received other comments that were general in nature and raised issues of specific medical illnesses and medical treatments. All of the issues raised are outside of the scope of this final order for 2021 and do not impact the original analysis involved in finalizing the 2021 APQ.

Analysis for Final Adjusted 2021 Aggregate Production Quotas and Assessment of Annual Needs

In determining the final adjusted 2021 APQ and AAN, DEA considered the above comments relevant to this final order for calendar year 2021, along with the factors set forth in 21 CFR 1303.13 and 21 CFR 1315.13, in accordance with 21 U.S.C. 826(a). DEA has also considered other relevant factors, including the 2020 year-end inventories, initial 2021 manufacturing and import quotas, 2021 export requirements, actual and projected 2021 sales, research and product development requirements, additional applications received, and the extent of any diversion of the controlled substance in the class. Based on all of the above, the Administrator is adjusting the 2021 APQ for the following: 3,4-Methylenedioxymethamphetamine (MDMA), 4,4'-Dimethylaminorex, Dimethyltryptamine (DMT), Lisdexamfetamine, Methiopropamine, Psilocybin, Psilocyn, and Phenylacetone. This final order reflects those adjustments.


[top] Pursuant to the above, the Administrator hereby finalizes the 2021 APQ for the following schedule I and II controlled substances and the 2021 AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: page 63063

page 63064page 63065page 63066page 63067


[top] 
Basic class Final adjusted 2021 quotas (g)
Schedule I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 20
1-(1-Phenylcyclohexyl)pyrrolidine 30
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) 30
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) 30
1-Benzylpiperazine 25
1-Methyl-4-phenyl-4-propionoxypiperidine 10
1-[1-(2-Thienyl)cyclohexyl]piperidine 15
2'-fluoro 2-fluorofentanyl 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) 30
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) 100
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) 30
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) 25
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) 30
2,5-Dimethoxy-4-ethylamphetamine (DOET) 25
2,5-Dimethoxy-4-n-propylthiophenethylamine 25
2,5-Dimethoxyamphetamine (DMA) 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) 30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) 30
3,4,5-Trimethoxyamphetamine 30
3,4-Methylenedioxyamphetamine (MDA) 55
3,4-Methylenedioxymethamphetamine (MDMA) 3,200
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 40
3,4-Methylenedioxy-N-methylcathinone (methylone) 40
3,4-Methylenedioxypyrovalerone (MDPV) 35
3-FMC; 3-Fluoro-N-methylcathinone 25
3-Methylfentanyl 30
3-Methylthiofentanyl 30
4'-Methyl acetyl fentanyl 30
4,4'-Dimethylaminorex 30
4-Bromo-2,5-dimethoxyamphetamine (DOB) 30
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) 25
4-Chloro-a-pyrrolidinovalerophenone (4-chloro-alpha-PVP) 25
4CN-Cumyl-Butanica, 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide 25
4F-MDMB-BINACA 30
4-Fluoroisobutyryl fentanyl 30
4-FMC; Flephedrone 25
4-MEC; 4-Methyl-N-ethylcathinone 25
4-Methoxyamphetamine 150
4-Methyl-2,5-dimethoxyamphetamine (DOM) 25
4-Methylaminorex 25
4-Methyl-N-methylcathinone (mephedrone) 45
4-Methyl-a-ethylaminopentiophenone (4-MEAP) 25
4-Methyl-a-pyrrolidinohexiophenone (MPHP) 25
4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) 25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 50
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) 40
5F-CUMYL-PINACA 25
5F-EDMB-PINACA 25
5F-MDMB-PICA 25
5F-AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 25
5F-CUMYL-P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide) 25
5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) 30
5F-AMB (methyl 2-(1-(5-fluoropentyl)-1 H -indazole-3-carboxamido)-3-methylbutanoate) 30
5F-APINACA; 5F-AKB48 ( N -(adamantan-1-yl)-1-(5-fluoropentyl)-1 H -indazole-3-carboxamide) 30
5-Fluoro-PB-22; 5F-PB-22 20
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1 H- indol- 3-yl](2,2,3,3-tetramethylcyclopropyl)methanone 25
5-Methoxy-3,4-methylenedioxyamphetamine 25
5-Methoxy-N,N-diisopropyltryptamine 25
5-Methoxy-N,N-dimethyltryptamine 35
AB-CHMINACA 30
AB-FUBINACA 50
AB-PINACA 30
ADB-FUBINACA ( N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide) 30
Acetorphine 25
Acetyl Fentanyl 100
Acetyl- alpha -methylfentanyl 30
Acetyldihydrocodeine 30
Acetylmethadol 25
Acryl Fentanyl 25
ADB-PINACA ( N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 H -indazole-3-carboxamide) 50
AH-7921 30
All other tetrahydrocannabinol 1,000
Allylprodine 25
Alphacetylmethadol 25
alpha- Ethyltryptamine 25
Alphameprodine 25
Alphamethadol 25
Alphaprodine 25
alpha -Methylfentanyl 30
alpha -Methylthiofentanyl 30
alpha -Methyltryptamine (AMT) 25
alpha -Pyrrolidinobutiophenone (a-PBP) 25
alpha -Pyrrolidinoheptaphenone (PV8) 25
alpha- Pyrrolidinohexanophenone (a-PHP) 25
alpha -Pyrrolidinopentiophenone (a-PVP) 25
Aminorex 25
Anileridine 20
APINCA, AKB48 ( N -(1-adamantyl)-1-pentyl-1 H -indazole-3-carboxamide) 25
Benzethidine 25
Benzylmorphine 30
Betacetylmethadol 25
beta -Hydroxy-3-methylfentanyl 30
beta -Hydroxyfentanyl 30
beta -Hydroxythiofentanyl 30
beta -Methyl fentanyl 30
beta -Phenyl fentanyl 30
Betameprodine 25
Betamethadol 4
Betaprodine 25
Brorphine 30
Bufotenine 15
Butylone 25
Butyryl fentanyl 30
Cathinone 40
Clonitazene 25
Codeine methylbromide 30
Codeine-N-oxide 192
Cyclopentyl Fentanyl 30
Cyclopropyl Fentanyl 20
Cyprenorphine 25
d-9-THC 384,460
Desomorphine 25
Dextromoramide 25
Diapromide 20
Diethylthiambutene 20
Diethyltryptamine 25
Difenoxin 9,200
Dihydromorphine 753,500
Dimenoxadol 25
Dimepheptanol 25
Dimethylthiambutene 20
Dimethyltryptamine 3,200
Dioxyaphetyl butyrate 25
Dipipanone 25
Drotebanol 25
Ethylmethylthiambutene 25
Etorphine 30
Etoxeridine 25
Fenethylline 30
Fentanyl carbamate 30
Fentanyl related substances 600
FUB-144 25
FUB-AKB48 25
FUB-AMB, MMB-Fubinaca, AMB-Fubinaca 25
Furanyl fentanyl 30
Furethidine 25
gamma -Hydroxybutyric acid 29,417,000
Heroin 45
Hydromorphinol 40
Hydroxypethidine 25
Ibogaine 30
Isobutyryl Fentanyl 25
JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) 45
JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) 30
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) 35
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) 30
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) 30
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) 30
Ketobemidone 30
Levomoramide 25
Levophenacylmorphan 25
Lysergic acid diethylamide (LSD) 40
MAB-CHMINACA; ADB-CHMINACA ( N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 H -indazole-3-carboxamide) 30
MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1 H -indole-3-carboxamido)-3,3-dimethylbutanoate) 30
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1 H -indazole-3-carboxamido)-3,3-dimethylbutanoate) 30
MMB-CHMICA-(AMB-CHMICA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate 25
Marihuana 2,000,000
Marihuana extract 500,000
Mecloqualone 30
Mescaline 25
Methaqualone 60
Methcathinone 25
Methiopropamine 30
Methyoxyacetyl fentanyl 30
Methyldesorphine 5
Methyldihydromorphine 25
Morpheridine 25
Morphine methylbromide 5
Morphine methylsulfonate 5
Morphine-N-oxide 150
MT-45 30
Myrophine 25
NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate 25
N,N -Dimethylamphetamine 25
Naphyrone 25
N -Ethyl-1-phenylcyclohexylamine 25
N -Ethyl-3-piperidyl benzilate 10
N -Ethylamphetamine 24
N- Ethylhexedrone 25
N- Ethylpentylone, ephylone 30
N -Hydroxy-3,4-methylenedioxyamphetamine 24
N-Methyl-3-Piperidyl Benzilate 30
Nicocodeine 25
Nicomorphine 25
Noracymethadol 25
Norlevorphanol 2,550
Normethadone 25
Normorphine 40
Norpipanone 25
Ocfentanil 25
Ortho-fluorofentanyl, 2-fluorofentanyl 30
ortho -Fluoroacryl fentanyl 30
ortho -Fluorobutyryl fentanyl 30
ortho -Fluoroisobutyryl fentanyl 30
ortho -Methyl acetylfentanyl 30
ortho -Methyl methoxyacetyl fentanyl 30
Para-chloroisobutyryl fentanyl 30
Para-fluorofentanyl 25
Para-fluorobutyryl fentanyl 25
para -Fluoro furanyl fentanyl 30
para -Methylfentanyl 30
Para-methoxybutyryl fentanyl 30
Parahexyl 5
PB-22; QUPIC 20
Pentedrone 25
Pentylone 25
Phenadoxone 25
Phenampromide 25
Phenomorphan 25
Phenoperidine 25
Phenyl fentanyl 30
Pholcodine 5
Piritramide 25
Proheptazine 25
Properidine 25
Propiram 25
Psilocybin 6,000
Psilocyn 3,500
Racemoramide 25
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) 45
SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) 30
Tetrahydrofuranyl fentanyl 15
Thebacon 25
Thiafentanil 25
Thiofentanyl 25
Thiofuranyl fentanyl 30
THJ-2201 ( [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) 30
Tilidine 25
Trimeperidine 25
UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 25
U-47700 30
Valeryl fentanyl 25
Schedule II
1-Phenylcyclohexylamine 15
1-Piperidinocyclohexanecarbonitrile 25
4-Anilino-N-phenethyl-4-piperidine (ANPP) 937,758
Alfentanil 3,260
Alphaprodine 25
Amobarbital 20,100
Bezitramide 25
Carfentanil 20
Cocaine 68,576
Codeine (for conversion) 1,612,500
Codeine (for sale) 27,616,684
D-amphetamine (for sale) 21,200,000
D,l-amphetamine 21,200,000
D-amphetamine (for conversion) 16,068,789
Dextropropoxyphene 35
Dihydrocodeine 156,713
Dihydroetorphine 25
Diphenoxylate (for conversion) 14,100
Diphenoxylate (for sale) 770,800
Ecgonine 68,576
Ethylmorphine 30
Etorphine hydrochloride 32
Fentanyl 731,452
Glutethimide 25
Hydrocodone (for conversion) 1,250
Hydrocodone (for sale) 30,821,224
Hydromorphone 2,743,101
Isomethadone 30
L-amphetamine 30
Levo-alphacetylmethadol (LAAM) 25
Levomethorphan 30
Levorphanol 26,495
Lisdexamfetamine 22,500,000
L-methamphetamine 587,229
Meperidine 856,695
Meperidine Intermediate-A 30
Meperidine Intermediate-B 30
Meperidine Intermediate-C 30
Metazocine 15
Methadone (for sale) 25,619,700
Methadone Intermediate 27,673,600
Methamphetamine 50
D-methamphetamine (for conversion) 485,020
D-methamphetamine (for sale) 40,000
Methylphenidate (for conversion) 15,300,000
Methylphenidate (for sale) 57,438,334
Metopon 25
Moramide-intermediate 25
Morphine (for conversion) 3,376,696
Morphine (for sale) 26,505,995
Nabilone 62,000
Norfentanyl 25
Noroxymorphone (for conversion) 22,044,741
Noroxymorphone (for sale) 376,000
Oliceridine 22,500
Opium (powder) 250,000
Opium (tincture) 530,837
Oripavine 33,010,750
Oxycodone (for conversion) 620,887
Oxycodone (for sale) 57,110,032
Oxymorphone (for conversion) 28,204,371
Oxymorphone (for sale) 563,174
Pentobarbital 30,766,670
Phenazocine 25
Phencyclidine 35
Phenmetrazine 25
Phenylacetone 6,100,000
Piminodine 25
Racemethorphan 5
Racemorphan 5
Remifentanil 3,000
Secobarbital 172,100
Sufentanil 4,000
Tapentadol 13,447,541
Thebaine 57,137,944
List I Chemicals
Ephedrine (for conversion) 100
Ephedrine (for sale) 4,136,000
Phenylpropanolamine (for conversion) 14,878,320
Phenylpropanolamine (for sale) 16,690,000
Pseudoephedrine (for conversion) 1,000
Pseudoephedrine (for sale) 174,246,000


The Administrator further proposes that APQ for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero.

Anne Milgram,

Administrator.

[FR Doc. 2021-24921 Filed 11-10-21; 4:15 pm]

BILLING CODE 4410-09-P